Alogliptin Rejection Dents Takeda’s Diabetes Franchise
This article was originally published in The Pink Sheet Daily
Executive Summary
Latest “complete response” letter for Takeda’s DPP-4 inhibitor is “not specific” to cardiovascular outcomes. But the delay does not bode well for entry into the crowded DPP-4 space.
You may also be interested in...
Use Of Pre-Approval CV Data From Ongoing Trial Gets Once-Over At Canagliflozin Panel
There is no statistical reason not to allow a single trial to provide pre-approval and post-approval cardiovascular hazard ratios for a diabetes drug, FDA says, but Janssen’s canagliflozin would be the first. The Endocrinologic and Metabolic Drugs Advisory Committee backed approval 10-5.
Merck Committed To Animal Health, Consumer Care, Frazier Says
In a week that saw Pfizer sell a non-core business to Nestle for five times sales, CEO Ken Frazier says Merck’s non-core businesses “complement” its R&D-driven pharma business.
Merck Committed To Animal Health, Consumer Care, Frazier Says
In a week that saw Pfizer sell a non-core business to Nestle for five times sales, CEO Ken Frazier says Merck’s non-core businesses “complement” its R&D-driven pharma business.